Clinical trial
Gene Therapy in Treating Patients With Advanced Bladder Cancer
NCT00003167 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003167 |
|---|---|
| Title | Gene Therapy in Treating Patients With Advanced Bladder Cancer |
| Official title | A Phase I Trial of Intravesical Ad-p53 Treatment in Locally Advanced and Metastatic Bladder Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder |
| Intervention type | Biological |
| Interventions | Ad5CMV-p53 gene |
| Enrollment | 24 |
| Start date | May 1, 1998 |
| Primary completion | Dec 1, 2002 |
| First posted | Nov 25, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: